GlassScriptPhysician profile
Laura J Kohler
NPI 1679933956
$4,728.39
in general payments reported to CMS, 2019-2025
45 companies · $454 in 2025
The $454 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $177 · 2021: $689 · 2022: $646 · 2023: $2,065 · 2024: $251 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,770.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $476.84 | 2021-2023 | Cabometyx |
| Lilly USA, LLC | $330.21 | 2021-2025 | Verzenio |
| Janssen Biotech, INC. | $322.79 | 2020-2025 | Darzalex, Tecvayli, Erleada |
| Genentech USA, INC. | $269.99 | 2022-2024 | Perjeta, Phesgo, Kadcyla |
| Novartis Pharmaceuticals Corporation | $267.75 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $236.66 | 2019-2022 | |
| Genzyme Corporation | $213.11 | 2021-2023 | |
| Genmab U.S., INC. | $208.96 | 2023-2025 | Epkinly |
| Incyte Corporation | $205.16 | 2021-2023 | Jakafi |
| Alexion Pharmaceuticals, INC. | $176.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $164.94 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.50 | 2022-2023 | |
| Glaxosmithkline, LLC. | $130.14 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Regeneron Healthcare Solutions, INC. | $130.02 | 2019 | |
| Medtronic, INC. | $115.38 | 2024 | Signia |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $102.37 | 2022-2024 | Brukinsa |
| Daiichi Sankyo INC. | $92.15 | 2022-2025 | Datroway, Enhertu |
| Celgene Corporation | $91.04 | 2021-2023 | Pomalyst, Opdualag, Reblozyl |
| Astellas Pharma US INC | $90.36 | 2023 | Padcev, Cresemba, Xospata |
| Amgen INC. | $83.56 | 2023 | Blincyto, Kyprolis, Nplate |
| Taiho Oncology, INC. | $76.04 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $64.67 | 2023-2025 | Keytruda, Welireg |
| Sobi, INC | $59.19 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $58.73 | 2021-2023 | Calquence, Enhertu |
| Eisai INC. | $58.38 | 2023 | |
| Deciphera Pharmaceuticals INC. | $53.59 | 2023-2025 | Qinlock |
| Tersera Therapeutics LLC | $49.23 | 2022-2023 | Zoladex |
| Pharmacyclics LLC, An Abbvie Company | $41.67 | 2023 | Imbruvica, Epkinly |
| Apellis Pharmaceuticals, INC. | $40.66 | 2023 | Empaveli |
| Caris Mpi, INC. | $38.73 | 2025 | Mi Cancer Seek |
| Rigel Pharmaceuticals, INC. | $32.02 | 2023 | Rezlidhia, Tavalisse |
| G1 Therapeutics, INC. | $31.78 | 2023 | Cosela |
| Adaptive Biotechnologies Corporation | $31.13 | 2024-2025 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $30.74 | 2023 | Fotivda |
| Sumitomo Pharma America, INC. | $23.58 | 2023 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $21.32 | 2023 | Cuvitru |
| Azurity Pharmaceuticals, INC. | $19.47 | 2025 | Danziten |
| Karyopharm Therapeutics INC. | $18.91 | 2025 | Xpovio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.71 | 2019 | |
| Pharmacosmos Therapeutics INC. | $17.70 | 2023 | Monoferric |
| Gilead Sciences, INC. | $16.63 | 2023 | |
| Alnylam Pharmaceuticals INC. | $16.07 | 2023 | Givlaari |
| Pfizer INC. | $14.81 | 2023 | |
| Abbvie INC. | $14.11 | 2024 | |
| Morphosys, US INC. | $13.59 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Kohler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.